Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983

Ronald de Wit; Iwona Skoneczna; Gedske Daugaard; Maria De Santis; August Garin; Nina Aass; Alfred J Witjes; Peter Hjorth Albers; Jeffery D White; José R Germa-Lluch; Sandrine Marreaud; Laurence Collette

doi:10.1200/JCO.2011.37.0171

Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983

Ronald de Wit
, Iwona Skoneczna
, Gedske Daugaard
, Maria De Santis
, August Garin
, Nina Aass
, Alfred J Witjes
, Peter Hjorth Albers
, Jeffery D White
, José R Germa-Lluch
, Sandrine Marreaud
, Laurence Collette

83 Citationer (Scopus)

Abstract

To compare the efficacy of four cycles of paclitaxel-bleomycin, etoposide, and cisplatin (T-BEP) to four cycles of bleomycin, etoposide, and cisplatin (BEP) in previously untreated patients with intermediate-prognosis germ-cell cancer (GCC).

Originalsprog	Engelsk
Tidsskrift	Journal of Clinical Oncology
Vol/bind	30
Udgave nummer	8
Sider (fra-til)	792-9
Antal sider	8
ISSN	0732-183X
DOI	https://doi.org/10.1200/JCO.2011.37.0171
Status	Udgivet - 2012

Adgang til dokumentet

10.1200/JCO.2011.37.0171

Citationsformater

de Wit, R., Skoneczna, I., Daugaard, G., De Santis, M., Garin, A., Aass, N., Witjes, A. J., Albers, P. H., White, J. D., Germa-Lluch, J. R., Marreaud, S., & Collette, L. (2012). Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983. Journal of Clinical Oncology, 30(8), 792-9. https://doi.org/10.1200/JCO.2011.37.0171

Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983. / de Wit, Ronald; Skoneczna, Iwona; Daugaard, Gedske et al.
I: Journal of Clinical Oncology, Bind 30, Nr. 8, 2012, s. 792-9.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

de Wit, R, Skoneczna, I, Daugaard, G, De Santis, M, Garin, A, Aass, N, Witjes, AJ, Albers, PH, White, JD, Germa-Lluch, JR, Marreaud, S & Collette, L 2012, 'Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983', Journal of Clinical Oncology, bind 30, nr. 8, s. 792-9. https://doi.org/10.1200/JCO.2011.37.0171

@article{ceb3f6584d0449d19361d41c634bdbf9,

title = "Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983",

abstract = "To compare the efficacy of four cycles of paclitaxel-bleomycin, etoposide, and cisplatin (T-BEP) to four cycles of bleomycin, etoposide, and cisplatin (BEP) in previously untreated patients with intermediate-prognosis germ-cell cancer (GCC).",

keywords = "Adolescent, Adult, Antibiotics, Antineoplastic, Antineoplastic Agents, Antineoplastic Agents, Phytogenic, Antineoplastic Combined Chemotherapy Protocols, Bleomycin, Cisplatin, Disease-Free Survival, Etoposide, Granulocyte Colony-Stimulating Factor, Humans, Male, Middle Aged, Neoplasms, Germ Cell and Embryonal, Paclitaxel, Treatment Outcome",

author = "\{de Wit\}, Ronald and Iwona Skoneczna and Gedske Daugaard and \{De Santis\}, Maria and August Garin and Nina Aass and Witjes, \{Alfred J\} and Albers, \{Peter Hjorth\} and White, \{Jeffery D\} and Germa-Lluch, \{Jos{\'e} R\} and Sandrine Marreaud and Laurence Collette",

year = "2012",

doi = "10.1200/JCO.2011.37.0171",

language = "English",

volume = "30",

pages = "792--9",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Spandidos Publications",

number = "8",

}

TY - JOUR

T1 - Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer

T2 - intergroup study EORTC 30983

AU - de Wit, Ronald

AU - Skoneczna, Iwona

AU - Daugaard, Gedske

AU - De Santis, Maria

AU - Garin, August

AU - Aass, Nina

AU - Witjes, Alfred J

AU - Albers, Peter Hjorth

AU - White, Jeffery D

AU - Germa-Lluch, José R

AU - Marreaud, Sandrine

AU - Collette, Laurence

PY - 2012

Y1 - 2012

N2 - To compare the efficacy of four cycles of paclitaxel-bleomycin, etoposide, and cisplatin (T-BEP) to four cycles of bleomycin, etoposide, and cisplatin (BEP) in previously untreated patients with intermediate-prognosis germ-cell cancer (GCC).

AB - To compare the efficacy of four cycles of paclitaxel-bleomycin, etoposide, and cisplatin (T-BEP) to four cycles of bleomycin, etoposide, and cisplatin (BEP) in previously untreated patients with intermediate-prognosis germ-cell cancer (GCC).

KW - Adolescent

KW - Adult

KW - Antibiotics, Antineoplastic

KW - Antineoplastic Agents

KW - Antineoplastic Agents, Phytogenic

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Bleomycin

KW - Cisplatin

KW - Disease-Free Survival

KW - Etoposide

KW - Granulocyte Colony-Stimulating Factor

KW - Humans

KW - Male

KW - Middle Aged

KW - Neoplasms, Germ Cell and Embryonal

KW - Paclitaxel

KW - Treatment Outcome

U2 - 10.1200/JCO.2011.37.0171

DO - 10.1200/JCO.2011.37.0171

M3 - Journal article

C2 - 22271474

SN - 0732-183X

VL - 30

SP - 792

EP - 799

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 8

ER -

Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater